Strong Increase of Leukocyte Apha‐galactosidase a Activity in Two Male Patients With Fabry Disease Following Oral Chaperone Therapy

Molecular genetics & genomic medicine - United States
doi 10.1002/mgg3.894
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Oral Chaperone Therapy Migalastat for Treating Fabry Disease: Enzymatic Response and Serum Biomarker Changes After One Year

Clinical Pharmacology and Therapeutics
Pharmacology
2019English

Screening for Fabry Disease in Patients With Chronic Kidney Disease: Limitations of Plasma -Galactosidase Assay as a Screening Test

Clinical Journal of the American Society of Nephrology
EpidemiologyNephrologyCritical CareTransplantationIntensive Care Medicine
2007English

Fabry Disease: Effective Tissue Substrate Depletion Following Enzyme Replacement in Α-Galactosidase a Deficient Mice. • 607

Pediatric Research
Child HealthPediatricsPerinatology
1997English

Alpha-Galactosidase a p.A143T, a Non-Fabry Disease-Causing Variant

Orphanet Journal of Rare Diseases
MedicineGeneticsPharmacology
2016English

Adipocytes Participate in Storage in Α-Galactosidase Deficiency (Fabry Disease)

Journal of Inherited Metabolic Disease
Genetics
2010English

Replacement of Α-Galactosidase a in Fabry Disease: Effect on Fibroblast Cultures Compared With Biopsied Tissues of Treated Patients

Virchows Archiv
MedicineForensic MedicinePathologyCell BiologyMolecular Biology
2008English

Receptor-Mediated Endocytosis of Α-Galactosidase a in Human Podocytes in Fabry Disease

PLoS ONE
Multidisciplinary
2011English

Reduction of Podocyte Globotriaosylceramide Content in Adult Male Patients With Fabry Disease With Amenable GLA Mutations Following 6 Months of Migalastat Treatment

Journal of Medical Genetics
Genetics
2017English

Effects of Enzyme Replacement Therapy and Antidrug Antibodies in Patients With Fabry Disease

Journal of the American Society of Nephrology : JASN
MedicineNephrology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy